Clinical Breakthrough: Repeat Psilocybin Dosing Drives Lasting Improvements for Cancer Patients

Sponsored:

Monday, April 20, 2026

Most clinical trials in psychedelic medicine have traditionally focused on the impact of a single treatment session. However, new data published this month is shifting that narrative, suggesting that psilocybin therapy may be more effective when structured as a repeatable, protocol-driven treatment rather than a one-time intervention. As regulatory pathways for these therapies accelerate, the focus is moving toward optimizing dosing schedules to maximize long-term patient outcomes. 

Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) released details today of a Phase 1 clinical study published in Frontiers in Public Health. Conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of Washington, the study evaluated the effects of a second psilocybin-assisted therapy session in metastatic cancer patients who had only partially responded to an initial treatment.

The study utilized the drug candidate PEX010, developed by Filament Health Corp., which Red Light Holland is currently in the process of acquiring. The results were statistically significant: Mean Hospital Anxiety and Depression Scale (HADS) scores improved from 15.08 at baseline to 9.00 within eight days of the second session. These benefits were sustained for up to 24 weeks, with 69% of participants falling below the clinical threshold for anxiety and depression following the second treatment. 

Critically, the proportion of patients reporting a "complete mystical experience," a psychological milestone often associated with stronger therapeutic durability, rose from 38% in the first session to 77% in the second. No serious adverse events were reported, even with higher dosing and optional booster administrations, supporting the safety profile of repeat-dosing strategies.

Currently, PEX010 is being supplied to more than 70 clinical research sites globally to support trials for PTSD, depression, and cancer-related distress. Filament Health also recently finalized new international licensing agreements and research shipments to support additional studies focused on these multi-session protocols. 

CEO Todd Shapiro noted that if psilocybin therapy proves most effective across multiple sessions, it will have significant implications for how the category evolves and how patient care is structured within the broader healthcare system. 

TRIP is trading at C$0.045/share, up 33.3%. TRUFF is trading at US$0.033/share, up 37.6%.

Sponsored: